Synonym
NDMC101; NDMC-101; NDMC 101; HS-Cm; HS Cm; HSCm;
IUPAC/Chemical Name
N-(4-Chloro-2-fluorophenyl)-2-hydroxybenzamide
InChi Key
NUQWCDAXACRITO-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H9ClFNO2/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17/h1-7,17H,(H,16,18)
SMILES Code
O=C(NC1=CC=C(Cl)C=C1F)C2=CC=CC=C2O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression.
In vitro activity:
NDMC101 markedly inhibited RANKL-induced formation of TRAP+ multinucleated cells in RAW264.7 and bone marrow macrophage cells (BMMs). Moreover, pit formation assay showed that NDMC101 significantly reduced the bone-resorbing activity of mature osteoclasts.
Reference: J Clin Immunol. 2012 Aug;32(4):762-77. https://pubmed.ncbi.nlm.nih.gov/22396044/
In vivo activity:
In CIA mice, oral administration of NDMC101 reduced arthritic index and mitigated bone erosion. Serum TNF-α and IL-1β concentrations in these mice were decreased significantly at the higher dose of 62.5 mg/kg.
Reference: J Clin Immunol. 2012 Aug;32(4):762-77. https://pubmed.ncbi.nlm.nih.gov/22396044/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
61.0 |
229.61 |
| DMSO:PBS (pH 7.2) (1:2) |
0.3 |
1.24 |
| Ethanol |
13.0 |
48.93 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
265.67
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. doi: 10.1007/s10875-012-9660-9. Epub 2012 Feb 23. PMID: 22396044.
In vitro protocol:
Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. doi: 10.1007/s10875-012-9660-9. Epub 2012 Feb 23. PMID: 22396044.
In vivo protocol:
Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. doi: 10.1007/s10875-012-9660-9. Epub 2012 Feb 23. PMID: 22396044.
1: Lee CC, Liu FL, Chen CL, Chen TC, Liu FC, Ahmed Ali AA, Chang DM, Huang HS. Novel inhibitors of RANKL-induced osteoclastogenesis: Design, synthesis, and biological evaluation of 6-(2,4-difluorophenyl)-3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-diones. Bioorg Med Chem. 2015 Aug 1;23(15):4522-32. doi: 10.1016/j.bmc.2015.06.007. Epub 2015 Jun 10. PubMed PMID: 26081760.
2: Lee CC, Liu FL, Chen CL, Chen TC, Chang DM, Huang HS. Discovery of 5-(2',4'-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis. Eur J Med Chem. 2015 Jun 15;98:115-26. doi: 10.1016/j.ejmech.2015.05.015. Epub 2015 May 15. PubMed PMID: 26005025.
3: Liou JT, Huang HS, Chiang ML, Lin CS, Yang SP, Ho LJ, Lai JH. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32. PubMed PMID: 24491838.
4: Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. doi: 10.1007/s10875-012-9660-9. Epub 2012 Feb 23. PubMed PMID: 22396044.
